

§ 4.118

38 CFR Ch. I (7–1–02 Edition)

	Rating
7715 Non-Hodgkin's lymphoma: With active disease or during a treatment phase	100
NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	
7716 Aplastic anemia: Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every six weeks	100
Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months ...	60
Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than once every three months	30
Requiring continuous medication for control	10
NOTE: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.	

[60 FR 49227, Sept. 22, 1995]

THE SKIN

§ 4.118 Schedule of ratings—skin.

	Rating
7800 Scars, disfiguring, head, face or neck: Complete or exceptionally repugnant deformity of one side of face or marked or repugnant bilateral disfigurement	50
Severe, especially if producing a marked and unsightly deformity of eyelids, lips, or auricles	30
Moderate; disfiguring	10
Slight	0
NOTE: When in addition to tissue loss and cicatrization there is marked discoloration, color contrast, or the like, the 50 percent rating under Code 7800 may be increased to 80 percent, the 30 percent to 50 percent, and the 10 percent to 30 percent. The most repugnant, disfiguring conditions, including scars and diseases of the skin, may be submitted for central office rating, with several unretouched photographs.	
7801 Scars, burns, third degree: Area or areas exceeding 1 square foot (0.1 m. ²)	40
Area or areas exceeding one-half square foot (0.05 m. ²)	30
Area or areas exceeding 12 square inches (77.4 cm. ²)	20
Area or areas exceeding 6 square inches (38.7 cm. ²)	10

	Rating
NOTE (1): Actual third degree residual involvement required to the extent shown under 7801.	
NOTE (2): Ratings for widely separated areas, as on two or more extremities or on anterior and posterior surfaces of extremities or trunk, will be separately rated and combined.	
7802 Scars, burns, second degree: Area or areas approximating 1 square foot (0.1 m. ²)	10
NOTE: See NOTE (2) under diagnostic code 7801.	
7803 Scars, superficial, poorly nourished, with repeated ulceration	10
7804 Scars, superficial, tender and painful on objective demonstration	10
NOTE: The 10 percent rating will be assigned, when the requirements are met, even though the location may be on tip of finger or toe, and the rating may exceed the amputation value for the limited involvement.	
7805 Scars, other. Rate on limitation of function of part affected.	
7806 Eczema: With ulceration or extensive exfoliation or crusting, and systemic or nervous manifestations, or exceptionally repugnant	50
With exudation or itching constant, extensive lesions, or marked disfigurement	30
With exfoliation, exudation or itching, if involving an exposed surface or extensive area	10
With slight, if any, exfoliation, exudation or itching, if on a nonexposed surface or small area	0
7807 Leishmaniasis, americana (mucocutaneous, espundia).	
7808 Leishmaniasis, old world (cutaneous, oriental sore).	
7809 Lupus erythematosus, discoid. (Not to be combined with ratings under diagnostic code 6350.)	
7810 Pinta.	
7811 Tuberculosis luposa (lupus vulgaris), active or inactive: Active	100
Inactive: See §§ 4.88b and 4.89.	
7812 Verruga peruana.	
7813 Dermatophytosis.	
7814 Tinea barbae.	
7815 Pemphigus.	
7816 Psoriasis.	
7817 Dermatitis exfoliativa.	
7818 New growths, malignant, skin. Rate scars, disfigurement, etc., on the extent of constitutional symptoms, physical impairment.	
7819 New growths, benign, skin. Rate as scars, disfigurement, etc. Unless otherwise provided, rate codes 7807 through 7819 as for eczema, dependent upon location, extent, and repugnant or otherwise disabling character of manifestations.	
NOTE: The most repugnant conditions may be submitted for central office rating with several unretouched photographs. Total disability ratings may be assigned without reference to Central Office in the most severe cases of pemphigus and dermatitis exfoliativa with constitutional symptoms.	

[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 43 FR 45262, Oct. 2, 1978]

Department of Veterans Affairs

§4.119

THE ENDOCRINE SYSTEM

§ 4.119 Schedule of ratings—endocrine system.

	Rat- ing
7900 Hyperthyroidism	
Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astointestinal symptoms	100
Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	60
Tachycardia, tremor, and increased pulse pressure or blood pressure	30
Tachycardia, which may be intermittent, and tremor, or; continuous medication required for control	10
NOTE (1): If disease of the heart is the predominant finding, evaluate as hyperthyroid heart disease (DC 7008) if doing so would result in a higher evaluation than using the criteria above.	
NOTE (2): If ophthalmopathy is the sole finding, evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of central visual acuity (DC 6061–6079).	
7901 Thyroid gland, toxic adenoma of	
Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or gastrointestinal symptoms	100
Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	60
Tachycardia, tremor, and increased pulse pressure or blood pressure	30
Tachycardia, which may be intermittent, and tremor, or; continuous medication required for control	10
NOTE (1): If disease of the heart is the predominant finding, evaluate as hyperthyroid heart disease (DC 7008) if doing so would result in a higher evaluation than using the criteria above.	
NOTE (2): If ophthalmopathy is the sole finding, evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of central visual acuity (DC 6061–6079).	
7902 Thyroid gland, nontoxic adenoma of	
With disfigurement of the head or neck	20
Without disfigurement of the head or neck	0
NOTE: If there are symptoms due to pressure on adjacent organs such as the trachea, larynx, or esophagus, evaluate under the diagnostic code for disability of that organ, if doing so would result in a higher evaluation than using this diagnostic code.	
7903 Hypothyroidism	
Cold intolerance, muscular weakness, cardiovascular involvement, mental disturbance (dementia, slowing of thought, depression), bradycardia (less than 60 beats per minute), and sleepiness ...	100
Muscular weakness, mental disturbance, and weight gain	60
Fatigability, constipation, and mental sluggishness ..	30
Fatigability, or; continuous medication required for control	10
7904 Hyperparathyroidism	
Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness	100
Gastrointestinal symptoms and weakness	60
Continuous medication required for control	10

	Rat- ing
NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction.	
7905 Hypoparathyroidism	
Marked neuromuscular excitability (such as convulsions, muscular spasms (tetany), or laryngeal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema)	100
Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure	60
Continuous medication required for control	10
7907 Cushing's syndrome	
As active, progressive disease including loss of muscle strength, areas of osteoporosis, hypertension, weakness, and enlargement of pituitary or adrenal gland	100
Loss of muscle strength and enlargement of pituitary or adrenal gland	60
With striae, obesity, moon face, glucose intolerance, and vascular fragility	30
NOTE: With recovery or control, evaluate as residuals of adrenal insufficiency or cardiovascular, psychiatric, skin, or skeletal complications under appropriate diagnostic code.	
7908 Acromegaly	
Evidence of increased intracranial pressure (such as visual field defect), arthropathy, glucose intolerance, and either hypertension or cardiomegaly	100
Arthropathy, glucose intolerance, and hypertension	60
Enlargement of acral parts or overgrowth of long bones, and enlarged sella turcica	30
7909 Diabetes insipidus	
Polyuria with near-continuous thirst, and more than two documented episodes of dehydration requiring parenteral hydration in the past year	100
Polyuria with near-continuous thirst, and one or two documented episodes of dehydration requiring parenteral hydration in the past year	60
Polyuria with near-continuous thirst, and one or more episodes of dehydration in the past year not requiring parenteral hydration	40
Polyuria with near-continuous thirst	20
7911 Addison's disease (Adrenal Cortical Hypofunction)	
Four or more crises during the past year	60
Three crises during the past year, or; five or more episodes during the past year	40
One or two crises during the past year, or; two to four episodes during the past year, or; weakness and fatigability, or; corticosteroid therapy required for control	20